Matricelf（MTLF）株式概要バイオテクノロジー企業であるMatricelf Ltd.は、様々な病状に対応する自己組織工学のプラットフォームを開発している。 詳細MTLF ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析過去1年間で株主の希薄化は大幅に進んだ IL市場と比較して、過去 3 か月間の株価の変動が非常に大きい収益が 100 万ドル未満 ( ₪0 )過去5年間で収益は年間17.2%減少しました。 +1 さらなるリスクすべてのリスクチェックを見るMTLF Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₪Current Price₪2.73該当なし内在価値ディスカウントEst. Revenue$PastFuture-28m12016201920222025202620282031Revenue ₪1.0Earnings ₪0.2AdvancedSet Fair ValueView all narrativesMatricelf Ltd 競合他社Grace BreedingSymbol: TASE:GRACMarket cap: ₪69.4mG.F.C Green Fields CapitalSymbol: TASE:GFC-MMarket cap: ₪160.8mClal Biotechnology IndustriesSymbol: TASE:CBIMarket cap: ₪40.6mBioLineRxSymbol: TASE:BLRXMarket cap: ₪39.3m価格と性能株価の高値、安値、推移の概要Matricelf過去の株価現在の株価₪2.7352週高値₪8.5352週安値₪2.04ベータ0.341ヶ月の変化-5.07%3ヶ月変化-19.08%1年変化16.91%3年間の変化-37.76%5年間の変化-61.39%IPOからの変化-48.32%最新ニュースお知らせ • Jun 25Matricelf Initiates Ind Enabling Efficacy Study for Engineered Human Neural Tissue Implant in Chronic Spinal Cord InjuryMatricelf Ltd. announced the initiation of a pivotal preclinical efficacy study evaluating its engineered human neural tissue implant for the treatment of chronic spinal cord injury. The study is designed to generate efficacy data supporting the Company's preparations for a first in human clinical trial. The study is being conducted in accordance with a development framework previously discussed with the U.S. Food and Drug Administration (FDA) and is intended to serve as an IND enabling efficacy study. The program will evaluate functional, behavioral, and histological endpoints that are widely accepted as key measures of therapeutic efficacy in spinal cord injury research. The newly initiated study builds upon previously reported preclinical results demonstrating significant improvements in motor function, sensory recovery, and tissue regeneration following implantation of Matricelf's engineered neural tissue in spinal cord injury models. The current study is designed to further validate the therapeutic potential of the technology using a comprehensive efficacy framework intended to support future regulatory submissions and clinical development. The study will include 96 animals with chronic spinal cord injury and will assess motor and sensory recovery using established outcome measures, including BBB, CatWalk, Mechanical Allodynia, and Thermal Allodynia testing, alongside comprehensive histological analyses of tissue repair and regeneration at the injury site. The study is expected to continue for approximately 12 weeks. Matricelf anticipates receiving interim results during the Fourth Quarter of 2026 and final study results during the First Quarter of 2027. Matricelf is developing a personalized neural tissue implant designed to treat patients suffering from paralysis following spinal cord injury. The Company's technology combines patient derived cells and biomaterials to create an autologous engineered implant tailored to each individual patient. Subject to successful study outcomes, completion of ongoing development activities, regulatory approvals, and financing requirements, Matricelf plans to seek authorization to initiate its first clinical trial in humans.お知らせ • Jun 17Matricelf Completes GLP Safety Study for Engineered Neural Tissue ImplantMatricelf Ltd. announced the successful completion of its comprehensive GLP safety study for its engineered neural tissue implant, achieving all predefined study endpoints with no abnormal findings. The study evaluated key safety parameters including toxicology, tumorigenicity, and biodistribution in 248 animals monitored for up to 39 weeks following implantation. Results demonstrated no treatment related toxicity, no evidence of tumor formation, and no migration of the implant to distant organs or tissues, supporting the safety profile of the Company's lead therapeutic program. The GLP study was designed as an IND enabling safety program and represents a significant milestone in Matricelf's preparations for a first in human clinical trial. The successful completion of the study provides an important component of the Company's future regulatory submissions and advances its clinical development roadmap. Matricelf is developing a personalized neural tissue implant designed to treat patients suffering from paralysis following spinal cord injury. The Company's technology combines patient derived cells and biomaterials to create an autologous engineered implant tailored to each individual patient. Subject to successful completion of ongoing preclinical studies, regulatory approvals, and financing requirements, Matricelf plans to seek authorization to initiate its first clinical trial in humans.お知らせ • Mar 05Matricelf Ltd. Reports Positive RNA Sequencing Results Demonstrating Promising Safety Profile Of Its Personalized Spinal Cord ImplantMatricelf Ltd. announced positive results from advanced RNA sequencing analyses of its human tissue implant, supporting key safety characteristics required for progression toward clinical trials. The analyses were conducted as part of a comprehensive safety characterization program aligned with international regulatory standards, including requirements of the US FDA. Matricelf performed advanced genetic testing using single nucleus RNA sequencing technology seq snRNA on 4 separate implant batches to enable deep characterization of the cellular composition of its proprietary engineered neural tissue implant. The findings support that all cell populations within the implant are in a post mitotic state, meaning there was no evidence of proliferative or dividing cells. The results indicate normal developmental progression of the engineered tissue and demonstrate that the cells have reached a stable stage of differentiation without continued cell division. Importantly, the absence of proliferating cells significantly reduces potential risks such as uncontrolled cell growth or formation of unintended tissue, key considerations in the development of advanced cell based therapies. Matricelf is developing an autologous engineered neural tissue implant for patients suffering from paralysis due to spinal cord injury. The implant consists of both cellular and extracellular components derived from the patient's own body. The cellular component is generated from a blood sample collected from the patient, from which induced pluripotent stem cells iPSCs are produced. In parallel, an omentum tissue sample, a fatty tissue surrounding abdominal organs, is harvested to create a proprietary hydrogel serving as the extracellular scaffold. Using Matricelf's proprietary tissue engineering process, the cellular and extracellular components are combined to create a personalized engineered neural tissue implant intended to repair the patient's injured spinal cord. The positive RNA sequencing results represent an important milestone in the company's regulatory and clinical development pathway as it prepares for advanced preclinical studies and future human clinical trials.お知らせ • Feb 27Matricelf Ltd Appoints Ron Mayron as Active Chairman of the Board of DirectorsMatricelf Ltd. announced the appointment of Mr. Ron Mayron as Active Chairman of the Board of Directors. Mr. Mayron's appointment follows shareholder approval and submission of his formal Director Eligibility Declaration in accordance with the Israeli Companies Law. Mr. Mayron holds a BSc in Industrial Engineering and Management from Ben Gurion University and an MBA from Tel Aviv University. He has served as CEO and owner of RonMed Ltd. since 2015 and brings decades of executive leadership experience in the healthcare and life sciences sectors. Over the past 5 years, Mr. Mayron has served as a director in multiple public and private life sciences companies, including SimpliVity, InnoCan Pharma, IceCure Medical, BioLight, G Medical, Kadimastem, Entera Bio, DNA Biomedical Solutions, and Earmada . His broad board level experience spans biotechnology, medical devices, pharmaceuticals, and advanced therapeutic platforms. In his eligibility declaration, Mr. Mayron confirmed that he meets the statutory qualifications to serve as a director of a public company under Israeli law and that he is not classified as a director with accounting and financial expertise. He also confirmed that he does not hold shares or convertible securities of the Company at the time of appointment.New Risk • Feb 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪15m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 12% per year over the past 5 years. Shareholders have been substantially diluted in the past year (81% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (₪146.3m market cap, or US$46.5m).New Risk • Dec 23New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 71% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪15m free cash flow). Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (71% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (₪153.5m market cap, or US$48.2m).最新情報をもっと見るRecent updatesお知らせ • Jun 25Matricelf Initiates Ind Enabling Efficacy Study for Engineered Human Neural Tissue Implant in Chronic Spinal Cord InjuryMatricelf Ltd. announced the initiation of a pivotal preclinical efficacy study evaluating its engineered human neural tissue implant for the treatment of chronic spinal cord injury. The study is designed to generate efficacy data supporting the Company's preparations for a first in human clinical trial. The study is being conducted in accordance with a development framework previously discussed with the U.S. Food and Drug Administration (FDA) and is intended to serve as an IND enabling efficacy study. The program will evaluate functional, behavioral, and histological endpoints that are widely accepted as key measures of therapeutic efficacy in spinal cord injury research. The newly initiated study builds upon previously reported preclinical results demonstrating significant improvements in motor function, sensory recovery, and tissue regeneration following implantation of Matricelf's engineered neural tissue in spinal cord injury models. The current study is designed to further validate the therapeutic potential of the technology using a comprehensive efficacy framework intended to support future regulatory submissions and clinical development. The study will include 96 animals with chronic spinal cord injury and will assess motor and sensory recovery using established outcome measures, including BBB, CatWalk, Mechanical Allodynia, and Thermal Allodynia testing, alongside comprehensive histological analyses of tissue repair and regeneration at the injury site. The study is expected to continue for approximately 12 weeks. Matricelf anticipates receiving interim results during the Fourth Quarter of 2026 and final study results during the First Quarter of 2027. Matricelf is developing a personalized neural tissue implant designed to treat patients suffering from paralysis following spinal cord injury. The Company's technology combines patient derived cells and biomaterials to create an autologous engineered implant tailored to each individual patient. Subject to successful study outcomes, completion of ongoing development activities, regulatory approvals, and financing requirements, Matricelf plans to seek authorization to initiate its first clinical trial in humans.お知らせ • Jun 17Matricelf Completes GLP Safety Study for Engineered Neural Tissue ImplantMatricelf Ltd. announced the successful completion of its comprehensive GLP safety study for its engineered neural tissue implant, achieving all predefined study endpoints with no abnormal findings. The study evaluated key safety parameters including toxicology, tumorigenicity, and biodistribution in 248 animals monitored for up to 39 weeks following implantation. Results demonstrated no treatment related toxicity, no evidence of tumor formation, and no migration of the implant to distant organs or tissues, supporting the safety profile of the Company's lead therapeutic program. The GLP study was designed as an IND enabling safety program and represents a significant milestone in Matricelf's preparations for a first in human clinical trial. The successful completion of the study provides an important component of the Company's future regulatory submissions and advances its clinical development roadmap. Matricelf is developing a personalized neural tissue implant designed to treat patients suffering from paralysis following spinal cord injury. The Company's technology combines patient derived cells and biomaterials to create an autologous engineered implant tailored to each individual patient. Subject to successful completion of ongoing preclinical studies, regulatory approvals, and financing requirements, Matricelf plans to seek authorization to initiate its first clinical trial in humans.お知らせ • Mar 05Matricelf Ltd. Reports Positive RNA Sequencing Results Demonstrating Promising Safety Profile Of Its Personalized Spinal Cord ImplantMatricelf Ltd. announced positive results from advanced RNA sequencing analyses of its human tissue implant, supporting key safety characteristics required for progression toward clinical trials. The analyses were conducted as part of a comprehensive safety characterization program aligned with international regulatory standards, including requirements of the US FDA. Matricelf performed advanced genetic testing using single nucleus RNA sequencing technology seq snRNA on 4 separate implant batches to enable deep characterization of the cellular composition of its proprietary engineered neural tissue implant. The findings support that all cell populations within the implant are in a post mitotic state, meaning there was no evidence of proliferative or dividing cells. The results indicate normal developmental progression of the engineered tissue and demonstrate that the cells have reached a stable stage of differentiation without continued cell division. Importantly, the absence of proliferating cells significantly reduces potential risks such as uncontrolled cell growth or formation of unintended tissue, key considerations in the development of advanced cell based therapies. Matricelf is developing an autologous engineered neural tissue implant for patients suffering from paralysis due to spinal cord injury. The implant consists of both cellular and extracellular components derived from the patient's own body. The cellular component is generated from a blood sample collected from the patient, from which induced pluripotent stem cells iPSCs are produced. In parallel, an omentum tissue sample, a fatty tissue surrounding abdominal organs, is harvested to create a proprietary hydrogel serving as the extracellular scaffold. Using Matricelf's proprietary tissue engineering process, the cellular and extracellular components are combined to create a personalized engineered neural tissue implant intended to repair the patient's injured spinal cord. The positive RNA sequencing results represent an important milestone in the company's regulatory and clinical development pathway as it prepares for advanced preclinical studies and future human clinical trials.お知らせ • Feb 27Matricelf Ltd Appoints Ron Mayron as Active Chairman of the Board of DirectorsMatricelf Ltd. announced the appointment of Mr. Ron Mayron as Active Chairman of the Board of Directors. Mr. Mayron's appointment follows shareholder approval and submission of his formal Director Eligibility Declaration in accordance with the Israeli Companies Law. Mr. Mayron holds a BSc in Industrial Engineering and Management from Ben Gurion University and an MBA from Tel Aviv University. He has served as CEO and owner of RonMed Ltd. since 2015 and brings decades of executive leadership experience in the healthcare and life sciences sectors. Over the past 5 years, Mr. Mayron has served as a director in multiple public and private life sciences companies, including SimpliVity, InnoCan Pharma, IceCure Medical, BioLight, G Medical, Kadimastem, Entera Bio, DNA Biomedical Solutions, and Earmada . His broad board level experience spans biotechnology, medical devices, pharmaceuticals, and advanced therapeutic platforms. In his eligibility declaration, Mr. Mayron confirmed that he meets the statutory qualifications to serve as a director of a public company under Israeli law and that he is not classified as a director with accounting and financial expertise. He also confirmed that he does not hold shares or convertible securities of the Company at the time of appointment.New Risk • Feb 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪15m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 12% per year over the past 5 years. Shareholders have been substantially diluted in the past year (81% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (₪146.3m market cap, or US$46.5m).New Risk • Dec 23New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 71% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪15m free cash flow). Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (71% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (₪153.5m market cap, or US$48.2m).New Risk • Aug 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Israeli stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪15m free cash flow). Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (₪42.8m market cap, or US$12.7m).New Risk • Aug 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₪34.2m (US$9.98m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪12m free cash flow). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (₪34.2m market cap, or US$9.98m). Minor Risk Share price has been volatile over the past 3 months (7.3% average weekly change).お知らせ • Jul 21Matricelf Ltd, Annual General Meeting, Aug 24, 2025Matricelf Ltd, Annual General Meeting, Aug 24, 2025. Location: teshuva law offices, IsraelNew Risk • Jun 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪12m free cash flow). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (6.6% average weekly change). Market cap is less than US$100m (₪39.0m market cap, or US$11.2m).New Risk • Mar 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (5.6% average weekly change). Market cap is less than US$100m (₪57.5m market cap, or US$15.9m).New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 34% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (34% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (5.9% average weekly change). Market cap is less than US$100m (₪57.6m market cap, or US$15.9m).New Risk • Dec 31New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 5.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (5.7% average weekly change). Shareholders have been diluted in the past year (33% increase in shares outstanding). Market cap is less than US$100m (₪59.0m market cap, or US$16.2m).New Risk • Aug 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (6.0% average weekly change). Shareholders have been diluted in the past year (33% increase in shares outstanding). Market cap is less than US$100m (₪61.0m market cap, or US$16.1m).New Risk • Mar 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (6.4% average weekly change). Shareholders have been diluted in the past year (33% increase in shares outstanding). Market cap is less than US$100m (₪86.7m market cap, or US$24.2m).New Risk • Feb 20New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 33% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Shareholders have been diluted in the past year (33% increase in shares outstanding). Market cap is less than US$100m (₪64.2m market cap, or US$17.5m).お知らせ • Dec 09Matricelf Ltd, Annual General Meeting, Jan 14, 2024Matricelf Ltd, Annual General Meeting, Jan 14, 2024, at 10:00 Israel Standard Time.New Risk • Oct 29New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₪40.6m (US$9.98m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (₪40.6m market cap, or US$9.98m). Minor Risk Share price has been volatile over the past 3 months (7.3% average weekly change).New Risk • Aug 14New major risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (₪55.2m market cap, or US$14.7m).Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Board Director Stanley Hirsch was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Director Ruth Arnon was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.株主還元MTLFIL BiotechsIL 市場7D-2.4%-0.8%0.2%1Y16.9%-14.3%18.2%株主還元を見る業界別リターン: MTLF過去 1 年間で-14.3 % の収益を上げたIL Biotechs業界を上回りました。リターン対市場: MTLFは、過去 1 年間で18.2 % のリターンを上げたIL市場を下回りました。価格変動Is MTLF's price volatile compared to industry and market?MTLF volatilityMTLF Average Weekly Movement11.2%Biotechs Industry Average Movement7.6%Market Average Movement5.7%10% most volatile stocks in IL Market9.6%10% least volatile stocks in IL Market3.7%安定した株価: MTLFの株価は、 IL市場と比較して過去 3 か月間で変動しています。時間の経過による変動: MTLFの weekly volatility ( 11% ) は過去 1 年間安定していますが、依然としてILの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト201915Gil Hakimmatricelf.comバイオテクノロジー企業であるMatricelf Ltd.は、様々な病状に対応する自己組織工学のプラットフォームを開発している。同社の再生医療プラットフォームは、脊髄損傷、加齢黄斑変性症、パーキンソン病、心筋梗塞を含むさまざまな病状を治療することを意図しており、3Dバイオプリンティングにも対応している。Matricelf Ltdは2019年に法人化され、イスラエルのネス・ジオナを拠点としている。もっと見るMatricelf Ltd 基礎のまとめMatricelf の収益と売上を時価総額と比較するとどうか。MTLF 基礎統計学時価総額₪81.42m収益（TTM）-₪27.86m売上高(TTM)n/a0.0xP/Sレシオ-2.9xPER（株価収益率MTLF は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計MTLF 損益計算書（TTM）収益₪0売上原価₪578.00k売上総利益-₪578.00kその他の費用₪27.29m収益-₪27.86m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.95グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0%MTLF の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/30 18:12終値2026/06/30 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Matricelf Ltd 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jun 25Matricelf Initiates Ind Enabling Efficacy Study for Engineered Human Neural Tissue Implant in Chronic Spinal Cord InjuryMatricelf Ltd. announced the initiation of a pivotal preclinical efficacy study evaluating its engineered human neural tissue implant for the treatment of chronic spinal cord injury. The study is designed to generate efficacy data supporting the Company's preparations for a first in human clinical trial. The study is being conducted in accordance with a development framework previously discussed with the U.S. Food and Drug Administration (FDA) and is intended to serve as an IND enabling efficacy study. The program will evaluate functional, behavioral, and histological endpoints that are widely accepted as key measures of therapeutic efficacy in spinal cord injury research. The newly initiated study builds upon previously reported preclinical results demonstrating significant improvements in motor function, sensory recovery, and tissue regeneration following implantation of Matricelf's engineered neural tissue in spinal cord injury models. The current study is designed to further validate the therapeutic potential of the technology using a comprehensive efficacy framework intended to support future regulatory submissions and clinical development. The study will include 96 animals with chronic spinal cord injury and will assess motor and sensory recovery using established outcome measures, including BBB, CatWalk, Mechanical Allodynia, and Thermal Allodynia testing, alongside comprehensive histological analyses of tissue repair and regeneration at the injury site. The study is expected to continue for approximately 12 weeks. Matricelf anticipates receiving interim results during the Fourth Quarter of 2026 and final study results during the First Quarter of 2027. Matricelf is developing a personalized neural tissue implant designed to treat patients suffering from paralysis following spinal cord injury. The Company's technology combines patient derived cells and biomaterials to create an autologous engineered implant tailored to each individual patient. Subject to successful study outcomes, completion of ongoing development activities, regulatory approvals, and financing requirements, Matricelf plans to seek authorization to initiate its first clinical trial in humans.
お知らせ • Jun 17Matricelf Completes GLP Safety Study for Engineered Neural Tissue ImplantMatricelf Ltd. announced the successful completion of its comprehensive GLP safety study for its engineered neural tissue implant, achieving all predefined study endpoints with no abnormal findings. The study evaluated key safety parameters including toxicology, tumorigenicity, and biodistribution in 248 animals monitored for up to 39 weeks following implantation. Results demonstrated no treatment related toxicity, no evidence of tumor formation, and no migration of the implant to distant organs or tissues, supporting the safety profile of the Company's lead therapeutic program. The GLP study was designed as an IND enabling safety program and represents a significant milestone in Matricelf's preparations for a first in human clinical trial. The successful completion of the study provides an important component of the Company's future regulatory submissions and advances its clinical development roadmap. Matricelf is developing a personalized neural tissue implant designed to treat patients suffering from paralysis following spinal cord injury. The Company's technology combines patient derived cells and biomaterials to create an autologous engineered implant tailored to each individual patient. Subject to successful completion of ongoing preclinical studies, regulatory approvals, and financing requirements, Matricelf plans to seek authorization to initiate its first clinical trial in humans.
お知らせ • Mar 05Matricelf Ltd. Reports Positive RNA Sequencing Results Demonstrating Promising Safety Profile Of Its Personalized Spinal Cord ImplantMatricelf Ltd. announced positive results from advanced RNA sequencing analyses of its human tissue implant, supporting key safety characteristics required for progression toward clinical trials. The analyses were conducted as part of a comprehensive safety characterization program aligned with international regulatory standards, including requirements of the US FDA. Matricelf performed advanced genetic testing using single nucleus RNA sequencing technology seq snRNA on 4 separate implant batches to enable deep characterization of the cellular composition of its proprietary engineered neural tissue implant. The findings support that all cell populations within the implant are in a post mitotic state, meaning there was no evidence of proliferative or dividing cells. The results indicate normal developmental progression of the engineered tissue and demonstrate that the cells have reached a stable stage of differentiation without continued cell division. Importantly, the absence of proliferating cells significantly reduces potential risks such as uncontrolled cell growth or formation of unintended tissue, key considerations in the development of advanced cell based therapies. Matricelf is developing an autologous engineered neural tissue implant for patients suffering from paralysis due to spinal cord injury. The implant consists of both cellular and extracellular components derived from the patient's own body. The cellular component is generated from a blood sample collected from the patient, from which induced pluripotent stem cells iPSCs are produced. In parallel, an omentum tissue sample, a fatty tissue surrounding abdominal organs, is harvested to create a proprietary hydrogel serving as the extracellular scaffold. Using Matricelf's proprietary tissue engineering process, the cellular and extracellular components are combined to create a personalized engineered neural tissue implant intended to repair the patient's injured spinal cord. The positive RNA sequencing results represent an important milestone in the company's regulatory and clinical development pathway as it prepares for advanced preclinical studies and future human clinical trials.
お知らせ • Feb 27Matricelf Ltd Appoints Ron Mayron as Active Chairman of the Board of DirectorsMatricelf Ltd. announced the appointment of Mr. Ron Mayron as Active Chairman of the Board of Directors. Mr. Mayron's appointment follows shareholder approval and submission of his formal Director Eligibility Declaration in accordance with the Israeli Companies Law. Mr. Mayron holds a BSc in Industrial Engineering and Management from Ben Gurion University and an MBA from Tel Aviv University. He has served as CEO and owner of RonMed Ltd. since 2015 and brings decades of executive leadership experience in the healthcare and life sciences sectors. Over the past 5 years, Mr. Mayron has served as a director in multiple public and private life sciences companies, including SimpliVity, InnoCan Pharma, IceCure Medical, BioLight, G Medical, Kadimastem, Entera Bio, DNA Biomedical Solutions, and Earmada . His broad board level experience spans biotechnology, medical devices, pharmaceuticals, and advanced therapeutic platforms. In his eligibility declaration, Mr. Mayron confirmed that he meets the statutory qualifications to serve as a director of a public company under Israeli law and that he is not classified as a director with accounting and financial expertise. He also confirmed that he does not hold shares or convertible securities of the Company at the time of appointment.
New Risk • Feb 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪15m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 12% per year over the past 5 years. Shareholders have been substantially diluted in the past year (81% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (₪146.3m market cap, or US$46.5m).
New Risk • Dec 23New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 71% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪15m free cash flow). Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (71% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (₪153.5m market cap, or US$48.2m).
お知らせ • Jun 25Matricelf Initiates Ind Enabling Efficacy Study for Engineered Human Neural Tissue Implant in Chronic Spinal Cord InjuryMatricelf Ltd. announced the initiation of a pivotal preclinical efficacy study evaluating its engineered human neural tissue implant for the treatment of chronic spinal cord injury. The study is designed to generate efficacy data supporting the Company's preparations for a first in human clinical trial. The study is being conducted in accordance with a development framework previously discussed with the U.S. Food and Drug Administration (FDA) and is intended to serve as an IND enabling efficacy study. The program will evaluate functional, behavioral, and histological endpoints that are widely accepted as key measures of therapeutic efficacy in spinal cord injury research. The newly initiated study builds upon previously reported preclinical results demonstrating significant improvements in motor function, sensory recovery, and tissue regeneration following implantation of Matricelf's engineered neural tissue in spinal cord injury models. The current study is designed to further validate the therapeutic potential of the technology using a comprehensive efficacy framework intended to support future regulatory submissions and clinical development. The study will include 96 animals with chronic spinal cord injury and will assess motor and sensory recovery using established outcome measures, including BBB, CatWalk, Mechanical Allodynia, and Thermal Allodynia testing, alongside comprehensive histological analyses of tissue repair and regeneration at the injury site. The study is expected to continue for approximately 12 weeks. Matricelf anticipates receiving interim results during the Fourth Quarter of 2026 and final study results during the First Quarter of 2027. Matricelf is developing a personalized neural tissue implant designed to treat patients suffering from paralysis following spinal cord injury. The Company's technology combines patient derived cells and biomaterials to create an autologous engineered implant tailored to each individual patient. Subject to successful study outcomes, completion of ongoing development activities, regulatory approvals, and financing requirements, Matricelf plans to seek authorization to initiate its first clinical trial in humans.
お知らせ • Jun 17Matricelf Completes GLP Safety Study for Engineered Neural Tissue ImplantMatricelf Ltd. announced the successful completion of its comprehensive GLP safety study for its engineered neural tissue implant, achieving all predefined study endpoints with no abnormal findings. The study evaluated key safety parameters including toxicology, tumorigenicity, and biodistribution in 248 animals monitored for up to 39 weeks following implantation. Results demonstrated no treatment related toxicity, no evidence of tumor formation, and no migration of the implant to distant organs or tissues, supporting the safety profile of the Company's lead therapeutic program. The GLP study was designed as an IND enabling safety program and represents a significant milestone in Matricelf's preparations for a first in human clinical trial. The successful completion of the study provides an important component of the Company's future regulatory submissions and advances its clinical development roadmap. Matricelf is developing a personalized neural tissue implant designed to treat patients suffering from paralysis following spinal cord injury. The Company's technology combines patient derived cells and biomaterials to create an autologous engineered implant tailored to each individual patient. Subject to successful completion of ongoing preclinical studies, regulatory approvals, and financing requirements, Matricelf plans to seek authorization to initiate its first clinical trial in humans.
お知らせ • Mar 05Matricelf Ltd. Reports Positive RNA Sequencing Results Demonstrating Promising Safety Profile Of Its Personalized Spinal Cord ImplantMatricelf Ltd. announced positive results from advanced RNA sequencing analyses of its human tissue implant, supporting key safety characteristics required for progression toward clinical trials. The analyses were conducted as part of a comprehensive safety characterization program aligned with international regulatory standards, including requirements of the US FDA. Matricelf performed advanced genetic testing using single nucleus RNA sequencing technology seq snRNA on 4 separate implant batches to enable deep characterization of the cellular composition of its proprietary engineered neural tissue implant. The findings support that all cell populations within the implant are in a post mitotic state, meaning there was no evidence of proliferative or dividing cells. The results indicate normal developmental progression of the engineered tissue and demonstrate that the cells have reached a stable stage of differentiation without continued cell division. Importantly, the absence of proliferating cells significantly reduces potential risks such as uncontrolled cell growth or formation of unintended tissue, key considerations in the development of advanced cell based therapies. Matricelf is developing an autologous engineered neural tissue implant for patients suffering from paralysis due to spinal cord injury. The implant consists of both cellular and extracellular components derived from the patient's own body. The cellular component is generated from a blood sample collected from the patient, from which induced pluripotent stem cells iPSCs are produced. In parallel, an omentum tissue sample, a fatty tissue surrounding abdominal organs, is harvested to create a proprietary hydrogel serving as the extracellular scaffold. Using Matricelf's proprietary tissue engineering process, the cellular and extracellular components are combined to create a personalized engineered neural tissue implant intended to repair the patient's injured spinal cord. The positive RNA sequencing results represent an important milestone in the company's regulatory and clinical development pathway as it prepares for advanced preclinical studies and future human clinical trials.
お知らせ • Feb 27Matricelf Ltd Appoints Ron Mayron as Active Chairman of the Board of DirectorsMatricelf Ltd. announced the appointment of Mr. Ron Mayron as Active Chairman of the Board of Directors. Mr. Mayron's appointment follows shareholder approval and submission of his formal Director Eligibility Declaration in accordance with the Israeli Companies Law. Mr. Mayron holds a BSc in Industrial Engineering and Management from Ben Gurion University and an MBA from Tel Aviv University. He has served as CEO and owner of RonMed Ltd. since 2015 and brings decades of executive leadership experience in the healthcare and life sciences sectors. Over the past 5 years, Mr. Mayron has served as a director in multiple public and private life sciences companies, including SimpliVity, InnoCan Pharma, IceCure Medical, BioLight, G Medical, Kadimastem, Entera Bio, DNA Biomedical Solutions, and Earmada . His broad board level experience spans biotechnology, medical devices, pharmaceuticals, and advanced therapeutic platforms. In his eligibility declaration, Mr. Mayron confirmed that he meets the statutory qualifications to serve as a director of a public company under Israeli law and that he is not classified as a director with accounting and financial expertise. He also confirmed that he does not hold shares or convertible securities of the Company at the time of appointment.
New Risk • Feb 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪15m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 12% per year over the past 5 years. Shareholders have been substantially diluted in the past year (81% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (₪146.3m market cap, or US$46.5m).
New Risk • Dec 23New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 71% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪15m free cash flow). Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (71% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (₪153.5m market cap, or US$48.2m).
New Risk • Aug 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Israeli stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪15m free cash flow). Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (₪42.8m market cap, or US$12.7m).
New Risk • Aug 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₪34.2m (US$9.98m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪12m free cash flow). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (₪34.2m market cap, or US$9.98m). Minor Risk Share price has been volatile over the past 3 months (7.3% average weekly change).
お知らせ • Jul 21Matricelf Ltd, Annual General Meeting, Aug 24, 2025Matricelf Ltd, Annual General Meeting, Aug 24, 2025. Location: teshuva law offices, Israel
New Risk • Jun 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪12m free cash flow). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (6.6% average weekly change). Market cap is less than US$100m (₪39.0m market cap, or US$11.2m).
New Risk • Mar 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (5.6% average weekly change). Market cap is less than US$100m (₪57.5m market cap, or US$15.9m).
New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 34% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (34% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (5.9% average weekly change). Market cap is less than US$100m (₪57.6m market cap, or US$15.9m).
New Risk • Dec 31New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 5.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (5.7% average weekly change). Shareholders have been diluted in the past year (33% increase in shares outstanding). Market cap is less than US$100m (₪59.0m market cap, or US$16.2m).
New Risk • Aug 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (6.0% average weekly change). Shareholders have been diluted in the past year (33% increase in shares outstanding). Market cap is less than US$100m (₪61.0m market cap, or US$16.1m).
New Risk • Mar 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (6.4% average weekly change). Shareholders have been diluted in the past year (33% increase in shares outstanding). Market cap is less than US$100m (₪86.7m market cap, or US$24.2m).
New Risk • Feb 20New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 33% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Shareholders have been diluted in the past year (33% increase in shares outstanding). Market cap is less than US$100m (₪64.2m market cap, or US$17.5m).
お知らせ • Dec 09Matricelf Ltd, Annual General Meeting, Jan 14, 2024Matricelf Ltd, Annual General Meeting, Jan 14, 2024, at 10:00 Israel Standard Time.
New Risk • Oct 29New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₪40.6m (US$9.98m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (₪40.6m market cap, or US$9.98m). Minor Risk Share price has been volatile over the past 3 months (7.3% average weekly change).
New Risk • Aug 14New major risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (₪55.2m market cap, or US$14.7m).
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Board Director Stanley Hirsch was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Director Ruth Arnon was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
